Study summary
A new pill plus immunotherapy modestly extended survival in later-line disease
10.9months median survival, vs 9.4 with regorafenib
What was tested
Zanzalintinib, a multi-target kinase inhibitor, plus atezolizumab against regorafenib for previously treated metastatic colorectal cancer that is not MSI-high.
What they found
- Median overall survival was 10.9 vs 9.4 months.
What it means
One of the first immunotherapy combinations to extend survival in standard (MSS) colorectal cancer.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.